The forecast for Genito Urinary System and Sex Hormones sales in Norway shows a trend of slight annual increases from 2024 to 2028. Specifically, the values per capita in US Dollars Purchasing Power Parity (PPP) are predicted to incrementally rise from 23.8 in 2024 to 24 in 2028. The year-on-year variation demonstrates minimal growth, with a 0.42% increase from 2024 to 2025 and stable figures from 2025 to 2027, followed by another small uptick in 2028. When considering Compound Annual Growth Rate (CAGR), the data exhibits a steady but modest growth rate over these five years. In 2023, the value stood at 23.7.
Future trends to watch for include possible influences from advancements in medical technologies and treatments, changes in demographic patterns, and healthcare policy adjustments in Norway. Continuous monitoring of these factors will be essential to anticipate any significant deviations from the predicted trend.
